Single-Patient IND for Mezigdomide for a Patient with Relapsed/Refractory Multiple Myeloma

This treatment is being provided to allow you access to an investigational medication for your multiple myeloma because standard treatments are no longer effective or appropriate for you. The drug is not FDA‑approved for routine use but has shown activity in patients with similar disease and is being made available to you through an FDA‑authorized single‑patient expanded access pathway, not as part of a research study. The goal is to attempt to treat your disease while closely monitoring your safety. Tests and procedures performed during treatment are part of routine medical care and required safety monitoring, and information collected may help improve understanding of the treatment’s risks for future patients.